CompanyUnclaimedBioTechHealthRNATherapeutics

Aptadir Therapeutics

RNA therapeutics that reprogram DNA methylation in disease

aptadir.com

Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.

About

Aptadir Therapeutics is a Milan-based biotech developing RNA inhibitor medicines (DiRs / aptaDiR and captaDiR platforms) intended to reverse aberrant DNA methylation in intractable genetic conditions and cancers. On 29 September 2026 it announced a €40M (~$45M) seed financing led by 4BIO Capital with participation from EXTEND and other European investors, to advance first-in-class demethylating candidates including Fragile X–related programs. Public site: aptadir.com.

Stage
seed
Founded
2024
Location
Milan, Italy
Added via
web
Ownership
unclaimed

Where to go

For people

For agents

Nothing listed yet.

Products

  • Aptadir DiR Platform — Gene-selective RNA inhibitors of DNMT1 for demethylating medicines · Other

Social profiles

Founders

← Directory